- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
CaseBioscience Launches New Biopreservation Solutions for Cell Therapy at ATW 2026
CaseCryo CTG DMSO and CaseStor HSS aim to advance next-generation cryopreservation and hypothermic storage for clinical cell therapy development.
Published on Feb. 8, 2026
Got story updates? Submit your updates here. ›
CaseBioscience, a research-driven biotechnology company, announced the launch of two new biopreservation solutions - CaseCryo CTG DMSO, a next-generation cryopreservation solution, and CaseStor HSS Hypothermic Storage Solution - at Advanced Therapies Week (ATW) 2026. These products are designed to support consistent quality and performance across cell therapy workflows, with a focus on long-term cell health and functional outcomes.
Why it matters
Cryopreservation and hypothermic storage are critical enabling technologies for cell and tissue therapies. CaseBioscience's new solutions are engineered to prioritize long-term cell performance, quality, and regulatory alignment, addressing key challenges faced by cell therapy developers and manufacturers.
The details
CaseCryo CTG DMSO and CaseStor HSS are manufactured under cGMP-aligned, ISO 13485:2016–certified quality systems at CaseBioscience's FDA-registered facility, applying regulatory and quality principles drawn from assisted reproductive technology (ART) workflows. Evaluations of these new biopreservation solutions have shown improved post-storage expansion of hPSCs, T cells, and MSCs, as well as enhanced long-term recovery and expansion of T cells and hPSCs compared to leading commercially available solutions.
- CaseBioscience will officially introduce CaseCryo CTG DMSO and CaseStor HSS at Advanced Therapies Week (ATW) 2026 on February 6, 2026.
- Drug Master Files (DMFs) have been filed for both products to support clinical development and regulatory alignment.
The players
CaseBioscience
A research-driven biotechnology company developing high-quality biopreservation and culture solutions that advance cell therapy and reproductive medicine.
Kevin Flynn, PhD
Chief Scientific Officer at CaseBioscience.
What they’re saying
“Cryopreservation and hypothermic storage are critical to enabling cell and tissue therapies. With CaseCryo CTG DMSO and CaseStor HSS, we're providing solutions built for clinical applications that prioritize long-term cell performance, quality, and regulatory rigor.”
— Kevin Flynn, PhD, Chief Scientific Officer (CaseBioscience)
What’s next
CaseBioscience continues to progress the development of additional formulations, such as CaseCryo CTG NON-DMSO for clinical applications, reflecting the company's ongoing efforts to advance alternative cryoprotectant strategies for cell therapy applications.
The takeaway
CaseBioscience's new biopreservation solutions, CaseCryo CTG DMSO and CaseStor HSS, are designed to support the consistent quality and long-term performance of cell therapies throughout the development and manufacturing workflows, addressing key challenges faced by the industry.
